{
  "id": 1922855,
  "title": "Bristol Myers' partner Biokin says bispecific ADC clears fourth cancer trial in China",
  "url": "https://urgent.news/2026/08/19/bristol-myers-partner-biokin-says-bispecific-adc-clears-fourth-cancer",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-19T11:05:05.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/bristol-myers-partner-biokin-says-bispecific-adc-clears-fourth-cancer-trial-in-china/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Chinese biotech Biokin said its EGFRxHER3 bispecific antibody-drug conjugate passed a late-stage China trial in a genetically-defined form of lung cancer, buoying optimism for a similar global study led by its partner Bristol Myers Squibb. ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}